Open AccessTHE EFFECT OF THE 8-WEEK ATORVASTATIN TREATMENT ON THE QUALITY OF LIFE OF HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME
Author(s) -
И. Д. Беспалова,
В. В. Калюжин,
Н. В. Рязанцева,
Юрий Анатольевич Медянцев,
Борис Юрьевич Мурашев,
Иван Анатольевич Осихов
Publication year - 2013
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2013-19-2-125-131
Subject(s) - atorvastatin , metabolic syndrome , medicine , quality of life (healthcare) , national cholesterol education program , prospective cohort study , obesity , nursing
Objective. To study the effect of the 8-week treatment with atorvastatin on the quality of life (QOL) of hypertensive patients with metabolic syndrome. Design and methods. An 8-week open prospective study included 35 patients with essential hypertension (stage II), associated with metabolic syndrome. Along with the complete clinical, laboratory and instrumental examination, taken in a specialized cardiology clinic, MOS SF-36® questionnaire was used to study the QOL during atorvastatin treatment. Results and conclusions. The 8-week atorvastatin treatment (20 to 40 mg/day titrated individually) both contributes to statistically signifi cant reduction of atherogenic fractions of cholesterol and provides a positive dynamics of subjective evaluation of QOL by SF-36® scales in hypertensive patients with metabolic syndrome.